ClinicalTrials.gg

Program

LPM3770164

A development code. Also written as “LPM3770164 sustained release tablet”, “LY03015 (LPM3770164 extended-release tablets)” and “[14C] LPM3770164”.

Its studies are mostly in Huntington Disease · Tardive Dyskinesia, led by Luye Pharma Group.

Furthest: phase 2, since Dec 9, 20246 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Luye Pharma Group62 open or runningphase 2since Dec 9, 2024Jan 9, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2022First study: phase 1 study in Huntington DiseaseFirst studyNCT05238701 · 104 enrolled · China
  2. Dec 19, 2023Phase 1 study in Tardive DyskinesiaNCT06216054 · 40 enrolled · China
  3. Jun 20, 2024Phase 1 study in Huntington DiseaseNCT06474650 · 16 enrolled · China
  4. Dec 9, 2024Phase 2 study in Tardive DyskinesiaNCT06731868 · 120 planned · China
  5. Apr 1, 20262 phase 1 studiesNCT07516899, NCT07671833

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07671833Healthy Participants · United States1CompletedMay 8, 202624
NCT07516899Huntington Disease · China1Not yet recruitingJun 30, 20268
NCT06731868Tardive Dyskinesia · China2RecruitingOct 31, 2025120
NCT06474650Huntington Disease · China1CompletedSep 25, 202416
NCT06216054Tardive Dyskinesia · China1CompletedJul 29, 202440
NCT05238701Huntington Disease · China1CompletedNov 4, 2023104

How it is read

Names in the registry

  • “LPM3770164 sustained release tablet”, 3 entries
  • “LY03015 (LPM3770164 extended-release tablets)”, 1 entry
  • “[14C] LPM3770164”, 1 entry
  • “LPM3770164 sustained release tablet 5 mg”, 1 entry
  • “LPM3770164 sustained release tablet 10 mg”, 1 entry

Codes read as this program: LY03015, LPM3770164.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.